Funder
National Institutes of Health
V Foundation for Cancer Research
Reference150 articles.
1. Mechanisms of disease: oncogene addiction--a rationale for molecular targeting in cancer therapy;Weinstein;Nat. Clin. Pract. Oncol.,2006
2. Cancer revoked: oncogenes as therapeutic targets;Felsher;Nat. Rev. Cancer,2003
3. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors;Piha-Paul;JNCI Cancer Spectr.,2020
4. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study;Amorim;Lancet Haematol.,2016
5. The c-MYC NHE III(1): function and regulation;Gonzalez;Annu. Rev. Pharmacol. Toxicol.,2010
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献